Hospira (now a subsidiary of Pfizer) filed a 351(k) application at the FDA on 16 December 2014 for Retacrit (epoetin...
The FDA has approved Retacrit (epoetin alfa-epbx) from Hospira/Pfizer, as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of...
Hospira, Inc. has announced that it has submitted a Biologics License Application (BLA) to the FDA for Retacrit, a proposed...
The FDA recommends caution when prescribing drugs that treat Anaemia for patients with Chronic Kidney Disease (CKD) since the drug...